Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6848229 | 0.82 | APEX1 (0.61) | APEX1MAPTHSD17B10TP53ALDH1A1 | |
| SCHEMBL10150422 | 0.82 | FFAR1 (0.53) | MAPTTP53FFAR1ALDH1A1 | |
| SCHEMBL10150451 | 0.81 | ALDH1A1 (0.44) | MAPTCRBNCYP3A4TP53MTNR1A | |
| SCHEMBL8667113 | 0.79 | MAPT (0.51) | APEX1CTSKMAPTHSD17B10CYP3A4 | |
| SCHEMBL24046386 | 0.77 | PKM (0.46) | APEX1CTSKCRBNBACE1CYP3A4 | |
| SCHEMBL3911561 | 0.77 | ALDH1A1 (0.51) | MAPTHSD17B10TP53ALDH1A1KDM4E | |
| SCHEMBL8870413 | 0.75 | APEX1 (0.64) | APEX1CRBNBACE1FFAR1ALDH1A1 | |
| SCHEMBL12350284 | 0.69 | PBRM1 (0.49) | HSD17B10CYP3A4ALDH1A1KDM4ECLK1 | |
| SCHEMBL24879103 | 0.69 | MAPT (0.47) | MAPTALDH1A1KDM4E | |
| SCHEMBL17325394 | 0.68 | GAA (0.49) | APEX1MAPTHSD17B10FFAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | APEX1 2881/4885CTSK 767/4885MAPT 899/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | APEX1 2881/4885CTSK 767/4885MAPT 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.